<List><item><source>MED</source><extId>27891093</extId><pmcid>5103413</pmcid><annotations><annotation><prefix>ase 1 and 2 trials (</prefix><exact>NCT00617253</exact><postfix>, NCT00389285, and N</postfix><tags><tag><name>NCT00617253</name><uri>http://identifiers.org/clinicaltrials/NCT00617253</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>rials (NCT00617253, </prefix><exact>NCT00389285</exact><postfix>, and NCT00095108) i</postfix><tags><tag><name>NCT00389285</name><uri>http://identifiers.org/clinicaltrials/NCT00389285</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>CT00617253, NCT00389285, and </prefix><exact>NCT00095108</exact><postfix>) in mRCC. </postfix><tags><tag><name>NCT00095108</name><uri>http://identifiers.org/clinicaltrials/NCT00095108</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>ase 1 and 2 trials (</prefix><exact>NCT01727089</exact><postfix> and NCT01806064)2 (</postfix><tags><tag><name>NCT01727089</name><uri>http://identifiers.org/clinicaltrials/NCT01727089</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>ls (NCT01727089 and </prefix><exact>NCT01806064</exact><postfix>)2 (Choueiri et al.,</postfix><tags><tag><name>NCT01806064</name><uri>http://identifiers.org/clinicaltrials/NCT01806064</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>or refractory non-Hodgkin lymphoma (</prefix><exact>NCT01015911</exact><postfix>)4. </postfix><tags><tag><name>NCT01015911</name><uri>http://identifiers.org/clinicaltrials/NCT01015911</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix> lorvotuzumab-mertansine is ongoing (</prefix><exact>NCT02452554</exact><postfix>). </postfix><tags><tag><name>NCT02452554</name><uri>http://identifiers.org/clinicaltrials/NCT02452554</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>herapy has recently been completed (</prefix><exact>NCT01625936</exact><postfix>5). </postfix><tags><tag><name>NCT01625936</name><uri>http://identifiers.org/clinicaltrials/NCT01625936</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation><annotation><prefix>mRCC of this combination is ongoing (</prefix><exact>NCT02187302</exact><postfix>). </postfix><tags><tag><name>NCT02187302</name><uri>http://identifiers.org/clinicaltrials/NCT02187302</uri></tag></tags><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider></annotation></annotations></item></List>